EP3837010C0 - Amides hétérocycliques à 5 à 7 éléments en tant qu'inhibiteurs de jak - Google Patents

Amides hétérocycliques à 5 à 7 éléments en tant qu'inhibiteurs de jak

Info

Publication number
EP3837010C0
EP3837010C0 EP19773584.8A EP19773584A EP3837010C0 EP 3837010 C0 EP3837010 C0 EP 3837010C0 EP 19773584 A EP19773584 A EP 19773584A EP 3837010 C0 EP3837010 C0 EP 3837010C0
Authority
EP
European Patent Office
Prior art keywords
membered heterocyclic
jak inhibitors
heterocyclic amides
amides
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19773584.8A
Other languages
German (de)
English (en)
Other versions
EP3837010B1 (fr
EP3837010A1 (fr
Inventor
Daniel D Long
Cameron Smith
Corbin Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Biopharma R&D IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D IP LLC filed Critical Theravance Biopharma R&D IP LLC
Publication of EP3837010A1 publication Critical patent/EP3837010A1/fr
Application granted granted Critical
Publication of EP3837010C0 publication Critical patent/EP3837010C0/fr
Publication of EP3837010B1 publication Critical patent/EP3837010B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP19773584.8A 2018-09-04 2019-09-03 Amides hétérocycliques à 5 à 7 éléments en tant qu'inhibiteurs de jak Active EP3837010B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726583P 2018-09-04 2018-09-04
PCT/US2019/049342 WO2020051139A1 (fr) 2018-09-04 2019-09-03 Amides hétérocycliques à 5 à 7 éléments en tant qu'inhibiteurs de jak

Publications (3)

Publication Number Publication Date
EP3837010A1 EP3837010A1 (fr) 2021-06-23
EP3837010C0 true EP3837010C0 (fr) 2023-07-05
EP3837010B1 EP3837010B1 (fr) 2023-07-05

Family

ID=68051893

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19773584.8A Active EP3837010B1 (fr) 2018-09-04 2019-09-03 Amides hétérocycliques à 5 à 7 éléments en tant qu'inhibiteurs de jak

Country Status (19)

Country Link
US (2) US10836763B2 (fr)
EP (1) EP3837010B1 (fr)
JP (1) JP7383696B2 (fr)
KR (1) KR20210056380A (fr)
CN (1) CN112703037B (fr)
AR (1) AR116114A1 (fr)
AU (1) AU2019335200A1 (fr)
BR (1) BR112021004063A2 (fr)
CL (1) CL2021000515A1 (fr)
CO (1) CO2021002976A2 (fr)
EA (1) EA202190686A1 (fr)
ES (1) ES2955717T3 (fr)
IL (1) IL281150B2 (fr)
MX (1) MX2021002484A (fr)
PH (1) PH12021550324A1 (fr)
SG (1) SG11202101751XA (fr)
TW (1) TWI793365B (fr)
UA (1) UA127328C2 (fr)
WO (1) WO2020051139A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3161899A4 (fr) 2014-06-30 2017-12-27 Black & Decker Inc. Bloc-batterie pour des outils électriques sans fil
CA3001542C (fr) 2015-11-03 2021-02-16 Theravance Biopharma R&D Ip, Llc Composes inhibiteurs de kinase jak pour le traitement de maladies respiratoires
PT3592742T (pt) 2017-03-09 2021-07-30 Theravance Biopharma R&D Ip Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
US10947229B2 (en) 2018-09-04 2021-03-16 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as JAK inhibitors
CN112638902A (zh) 2018-09-04 2021-04-09 施万生物制药研发Ip有限责任公司 用于制备jak抑制剂的方法及其中间体
ES2955717T3 (es) * 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2022081872A1 (fr) * 2020-10-16 2022-04-21 Gb008, Inc. Inhibiteurs de janus kinase

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP2740731B1 (fr) 2007-06-13 2016-03-23 Incyte Holdings Corporation Sels cristallines de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile
CN102131390A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2414340A1 (fr) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Composés utilisables pour le traitement de troubles à médiation par le récepteur métabotropique 5 au glutamate et leurs procédés d'utilisation
WO2011084486A1 (fr) 2009-12-21 2011-07-14 Epitherix, Llc 1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
JP6192839B2 (ja) 2013-12-05 2017-09-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
AU2015260905A1 (en) 2014-05-14 2016-12-01 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (fr) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Composés hétérocycliques utilisés comme inhibiteurs de erk
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
WO2017077283A1 (fr) * 2015-11-03 2017-05-11 Topivert Pharma Limited Dérivés 4,5,6,7-tétrahydro-1h-imidazo[4,5-c]pyridine et 1,4,5,6,7,8-héxahydroimidazo[4,5-d]azépine en tant qu'inhibiteurs de janus kinase
US10556901B2 (en) * 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
CA3001542C (fr) 2015-11-03 2021-02-16 Theravance Biopharma R&D Ip, Llc Composes inhibiteurs de kinase jak pour le traitement de maladies respiratoires
RU2019100559A (ru) * 2016-07-14 2020-07-14 Пфайзер Инк. Новые пиримидиновые карбоксамиды в качестве ингибиторов фермента ванин-1
PT3592742T (pt) * 2017-03-09 2021-07-30 Theravance Biopharma R&D Ip Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
BR112019022665A2 (pt) 2017-05-01 2020-05-19 Theravance Biopharma R&D Ip Llc métodos de tratamento usando um composto inibidor de jak
SG11201909376TA (en) 2017-05-01 2019-11-28 Theravance Biopharma R&D Ip Llc Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CN112638902A (zh) 2018-09-04 2021-04-09 施万生物制药研发Ip有限责任公司 用于制备jak抑制剂的方法及其中间体
ES2955717T3 (es) * 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
US10947229B2 (en) 2018-09-04 2021-03-16 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as JAK inhibitors
CA3113667A1 (fr) 2018-10-29 2020-05-07 Theravance Biopharma R&D Ip, Llc Compose de 2-azabicyclo hexane utilise en tant qu'inhibiteur de jak
BR112021016751B8 (pt) 2019-02-25 2023-11-21 Henan Medinno Pharmaceutical Tech Co Ltd Compostos, composições farmacêuticas e usos dos compostos
EP3934651A1 (fr) 2019-03-05 2022-01-12 Incyte Corporation Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途

Also Published As

Publication number Publication date
US20210024517A1 (en) 2021-01-28
SG11202101751XA (en) 2021-03-30
AU2019335200A1 (en) 2021-03-11
US10836763B2 (en) 2020-11-17
CN112703037B (zh) 2023-10-20
EA202190686A1 (ru) 2021-07-23
EP3837010B1 (fr) 2023-07-05
US20200071325A1 (en) 2020-03-05
US11713315B2 (en) 2023-08-01
AR116114A1 (es) 2021-03-31
JP2021535174A (ja) 2021-12-16
JP7383696B2 (ja) 2023-11-20
TWI793365B (zh) 2023-02-21
MX2021002484A (es) 2021-05-12
PH12021550324A1 (en) 2021-10-04
CN112703037A (zh) 2021-04-23
CO2021002976A2 (es) 2021-05-31
TW202024075A (zh) 2020-07-01
IL281150A (en) 2021-04-29
CL2021000515A1 (es) 2021-07-23
KR20210056380A (ko) 2021-05-18
IL281150B1 (en) 2023-11-01
IL281150B2 (en) 2024-03-01
UA127328C2 (uk) 2023-07-19
ES2955717T3 (es) 2023-12-05
WO2020051139A1 (fr) 2020-03-12
BR112021004063A2 (pt) 2021-05-25
EP3837010A1 (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
IL281150A (en) Heterocyclic amides with 5 to 7 atoms as JAK inhibitors
IL266214B (en) 5,4,2-tri-converted 4,2,1-triazolones used as dhodh inhibitors
SG10202110874TA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11202005881YA (en) Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK1249905A1 (zh) 作為lsd1抑制劑的雜環化合物
IL268004B (en) History of tyrosine amide as rho-kinase inhibitors
IL267090A (en) Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors and methods of using them
MY192059A (en) Heterocyclic amides as kinase inhibitors
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
IL281146A (en) Dimethyl amino aztidine amides as JAK inhibitors
IL273657A (en) Use of p38 inhibitors to reduce expression of dux4
EP3666770A4 (fr) Nouveaux composés hétérocycliques comme inhibiteurs de cdk8/19
IL269695A (en) Compounds useful as ALCAT 1 inhibitors
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
IL273974B1 (en) Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors, salts thereof and method for their synthesis
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
GB201708390D0 (en) Novel alpha-amino amide derivatives
IL277869A (en) Substituted propanamides as nuclease inhibitors
IL257168B (en) Use of 7-carboxybenzo[1,2,3]thiadiazole amides as plant stimulants

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045534

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220502

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20221027

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1584278

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019032217

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

P04 Withdrawal of opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230725

U01 Request for unitary effect filed

Effective date: 20230725

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20230728

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20230927

Year of fee payment: 5

Ref country code: GB

Payment date: 20230927

Year of fee payment: 5

U20 Renewal fee paid [unitary effect]

Year of fee payment: 5

Effective date: 20230927

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2955717

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20231205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231006

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231002

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231005

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231105

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231006

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019032217

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230705

26N No opposition filed

Effective date: 20240408